Tina
★    

India,
2016-05-26 15:58
(3685 d 15:45 ago)

Posting: # 16363
Views: 2,990
 

 Biowaiver for one strength/dose of non-linear PK [Design Issues]

Post reply
Dear all,
Iam currently working on a BE study (with an anticancer drug) in cancer patients for EU submission. A higher dose is linear whilst the lower dose (in a different group of cancer patients) is non-linear. BE study with a higher dose can be planned. However, being rare condition, lower dose/strength cant be planned. Could the group members kindly help with providing a solution to waive BE study with the lower dose/strength (with non-linear pk) please? The irony is some patients in the main indication could also receive the lower dose/strength…recruitment of such patients will still be an issue. Has anyone received biowaiver for non-linear PK drug by conduct of a single study and justifying the non-conduct of the other?
Thank you for the kind help.
Kind regards,
Tina

Edit: Category changed; see also this post #1. [Helmut]
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
431 visitors (0 registered, 431 guests [including 22 identified bots]).
Forum time: 07:44 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5